Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03586453 · ClinicalTrials.gov registry record · Phase 2

Osimertinib In EGFR Mutant Lung Cancer

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Dana-Farber Cancer Institute.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Phase 2
Development phase: 30
Enrollment target: 2
Study locations

NCT03586453: Recruiting Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Dana-Farber Cancer Institute.

NCT03586453 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03586453, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status: Phase 2
Development phase: 30 participants
Enrollment target: 2
Study locations

Study Summary

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: \- Osimertinib (Tagrisso)

Primary Outcome

Evaluated by comparing the genomic changes using targeted next generation sequencing in the post-osimertinib tumor to the pre-treatment tumor specimen.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

DRUG Osimertinib

Study Locations (2)

Massachusetts

Beth Israel Deaconess Medical Center - Boston
Dana-Farber Cancer Institute - Boston

Trial Details

Field	Value
Enrollment Target	30 participants
Start Date	2018-08-13
Est. Completion	2027-03-01
Phase	Phase 2

Dana-Farber Cancer Institute

781 total trials

What NCT03586453 shows while recruiting

NCT03586453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Osimertinib is the first listed.

NCT03586453 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03586453 about?

NCT03586453 is a clinical study titled "Osimertinib In EGFR Mutant Lung Cancer". This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: \- Osimertinib (Tagrisso)

What is the current status of trial NCT03586453?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-08-13. Estimated completion is 2027-03-01.

What conditions does trial NCT03586453 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT03586453?

The interventions under investigation include: Osimertinib (DRUG).

Who is sponsoring clinical trial NCT03586453?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03586453 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03586453's enrollment target sits among peer trials

30 110th of 130 higher than 17 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03586453, the US trial registry maintained by the National Library of Medicine. NCT03586453 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.